Amarin Corp. (AMRN) – Company Press Releases
-
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Wit
-
Amarin Reports Third Quarter 2023 Financial Results
-
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
-
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
-
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 20
-
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
-
Amarin to Present at the 2023 Cantor Global Healthcare Conference
-
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
-
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
-
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
-
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
-
Amarin Reports Second Quarter 2023 Financial Results
-
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
-
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
-
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
-
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
-
Amarin Appoints Patrick Holt as President and Chief Executive Officer
-
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
-
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
-
Amarin to Present at Two Upcoming Investor Conferences
-
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
-
BiomX Reports First Quarter 2023 Financial Results and Provides Business Update
-
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
-
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
-
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
-
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
-
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
-
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
-
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
-
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
-
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
-
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
-
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
-
Amarin Announces Board Departures
-
Amarin Announces Board Departures
-
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
-
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
-
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
-
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
-
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
-
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
-
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
-
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
-
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
-
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
-
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
-
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
Back to AMRN Stock Lookup
